Differential Clinical and Immunological Impacts of Anti–T‐Lymphocyte Globulin ( ATLG ) vs. Anti‐Thymocyte Globulin ( ATG ) in Preventing Graft‐Versus‐Host Disease Post‐Allogeneic Hematopoietic Stem Cell Transplantation: A Comparative Study
American Journal of Hematology · 2025-04 · 100 (4) · 626-637
DOI: 10.1002/ajh.27619 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift American Journal of Hematology, online erschienen am 04.02.2025. Verfasst von Anne Beatrice Notarantonio und 20 weiteren Autor:innen. Beteiligte Einrichtung: Service d'Hématologie, Hôpital Brabois, Nancy, France. Hauptthemen laut MEDLINE: Antilymphocyte Serum, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Neovii Pharmaceuticals.
Abstract (Originalsprache)
Both anti‐T‐lymphocyte globulin (ATLG‐Grafalon) and anti‐thymocyte globulin (ATG‐Thymoglobulin) prevent acute and chronic graft‐versus‐host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (allo‐HSCT). Despite distinct manufacturing and biological characteristics, the two brands of rabbit anti‐lymphocyte globulins have never been compared in a prospective way. In this monocentric study, 114 adult patients transplanted with a matched related or unrelated donor after receiving either ATG ( n = 50) or ATLG ( n = 64) were included to compare their clinical outcomes and broad immune reconstitution parameters. The use of ATLG, compared with ATG, was associated with a 2‐fold reduction in Grade II–IV acute GvHD incidence (Cox HR = 0.29; 95% CI 0.14–0.62, p = 0.006), similar relapse incidence, and improved severe GvHD and relapse‐free survival (GRFS) (Cox HR = 0.51; 95% CI 0.29–0.91, p = 0.027). Biologically, reduced IL‐15 but increased IL‐21 serum concentrations and a significant reduction of PD1+ T cells, mainly across all differentiated stages of CD8+ T cells, were observed in the ATLG group. Immunosequencing of vβ T cell receptor (TCR) repertoires showed similar quantitative characteristics in terms of clonality and diversity across the two groups but different qualitative features, with reduced hyper‐expanded T cell clones and higher variability in the distribution of complementarity‐determining region 3 (CDR3) lengths in the ATLG group. Altogether, these results suggest that ATLG more effectively regulates alloreactive T cell activation, leading to better prevention of acute GvHD while preserving the graft‐versus‐leukemia response. These findings led us to initiate a multicentric Phase III randomized trial comparing the two anti‐lymphocyte globulins. Trial Registration: The biological REAL GREFFE study was registered in clinicaltrial.gov under the number: NCT03357172.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service d'Hématologie, Hôpital Brabois, Nancy, France.
- CNRS UMR 7365, IMoPA, Biopôle de l'Université de Lorraine, Nancy, France.
- Biostatistics Independent Consultant, Pérouges, France.
- Inserm U1256 N-GERE, University of Lorraine, Nancy, France.
- Laboratoire d'histocompatilité-HLA, Hôpital Brabois, Nancy, France.
- Laboratoire d'Immunologie, Hôpital Brabois, Nancy, France.
ORCID-Profile: Maud D'Aveni-Piney, Sébastien Hergalant, Marie Thérèse Rubio
Förderung
- Neovii Pharmaceuticals
Zitieren
APA
Notarantonio, A. B., Morisset, S., Piucco, R., Pérès, M., Boulangé, L., Alitcher, A., Brouard, J., Monchablon, L., Campidelli, A., El Ouahabi, S., Guisnel, C., Moulin, C., Kicki, C., Roth-Guepin, G., Feugier, P., Bittencourt, M. C., Aarnink, A., D'Aveni-Piney, M., Hergalant, S., …, & Rubio, M. T. (2025). Differential Clinical and Immunological Impacts of Anti–T‐Lymphocyte Globulin ( ATLG ) vs. Anti‐Thymocyte Globulin ( ATG ) in Preventing Graft‐Versus‐Host Disease Post‐Allogeneic Hematopoietic Stem Cell Transplantation: A Comparative Study. American Journal of Hematology, 100(4), 626-637. https://doi.org/10.1002/ajh.27619
Vancouver
Notarantonio AB, Morisset S, Piucco R, Pérès M, Boulangé L, Alitcher A, et al. Differential Clinical and Immunological Impacts of Anti–T‐Lymphocyte Globulin ( ATLG ) vs. Anti‐Thymocyte Globulin ( ATG ) in Preventing Graft‐Versus‐Host Disease Post‐Allogeneic Hematopoietic Stem Cell Transplantation: A Comparative Study. American Journal of Hematology. 2025;100(4):626-637. doi:10.1002/ajh.27619
BibTeX
@article{Notarantonio2025,
author = {Notarantonio, Anne Beatrice and Morisset, Stéphane and Piucco, Romain and Pérès, Michaël and Boulangé, Laura and Alitcher, Alizée and Brouard, Jordan and Monchablon, Lucile and Campidelli, Arnaud and El Ouahabi, Siham and Guisnel, Charles and Moulin, Charline and Kicki, Céline and Roth-Guepin, Gabrielle and Feugier, Pierre and Bittencourt, Marcelo De Carvalho and Aarnink, Alice and D'Aveni-Piney, Maud and Hergalant, Sébastien and Pagliuca, Simona and Rubio, Marie Thérèse},
title = {Differential Clinical and Immunological Impacts of Anti–T‐Lymphocyte Globulin ( ATLG ) vs. Anti‐Thymocyte Globulin ( ATG ) in Preventing Graft‐Versus‐Host Disease Post‐Allogeneic Hematopoietic Stem Cell Transplantation: A Comparative Study},
journal = {American Journal of Hematology},
year = {2025},
volume = {100},
number = {4},
pages = {626--637},
doi = {10.1002/ajh.27619}
}
EUVIMED